Coronet
Coronet is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Coronet.
Coronet is a company.
Key people at Coronet.
Key people at Coronet.
Coronet Ventures is the Singapore-based venture investment arm of Cedars-Sinai Intellectual Property Company (CSIP), the innovation division of Cedars-Sinai Medical Center, focused on early-stage healthcare and biomedical startups.[1][2][4] Its mission is to build innovative companies that advance patient outcomes worldwide by bridging innovations from global hubs like Singapore and the Netherlands to the U.S. market, leveraging Cedars-Sinai's health system for piloting, scaling, and commercialization.[1][2] The firm targets "first-in-class and best-in-class" solutions in diagnostics, pharmaceuticals, medical devices, and digital health, providing portfolio companies with access to clinical trials, key opinion leaders, IP protection, FDA support, and the Cedars-Sinai Accelerator network.[1][2] As a joint venture with SEEDS Capital, it emphasizes U.S.-synergistic technologies from innovative economies.[4]
Launched as CSIP's first international investment initiative, Coronet Ventures established its Singapore operations to scout and fund regional biomedical startups, building on Cedars-Sinai's U.S. reputation and global partnerships.[1][2] Key leaders include CEO Nirdesh Gupta and Investment Director Colin Tan, both based in Singapore.[4] The firm has evolved from a U.S.-centric accelerator (supporting over 100 companies since 2017) to a global investor, with a notable 2023 fund commitment and lead investments like the US$7M seed round in Aevice Health's remote monitoring tech in May 2025.[1][3][4] This expansion deepens ties with partner nations, nurturing startups for Cedars-Sinai's mission of quality healthcare and IP commercialization.[1][2]
(Note: Search results reference a separate "Coronet" portfolio company that raised $175M, but context confirms this query targets the investment firm; the other appears unrelated.[5])
Coronet Ventures rides the wave of global healthcare innovation convergence, connecting Asia/Europe's R&D hubs to the U.S.'s massive market amid rising demand for AI-driven diagnostics, digital health, and chronic disease tools.[1][2][3] Timing aligns with post-pandemic acceleration in remote monitoring (e.g., Aevice investment) and biomed cross-border scaling, fueled by U.S. regulatory pathways and health system pilots.[1][3] Market forces like aging populations, IP commercialization needs, and Cedars-Sinai's data/clinical resources favor its model, influencing the ecosystem by de-risking international startups and fostering U.S.-Asia synergies in a fragmented $4T+ global healthcare sector.[1][2]
Coronet Ventures is poised to expand its portfolio amid booming digital health and biomed demand, potentially deepening Netherlands investments and chasing larger Series A/B rounds post its 2023 fund commitment.[1][4] Trends like AI diagnostics, personalized medicine, and U.S. market entry barriers will shape its path, amplifying Cedars-Sinai's global influence through more high-impact exits and collaborations.[1][2] As international healthcare M&A heats up, expect Coronet to solidify as a key bridge-builder, turning regional innovations into worldwide patient wins—echoing its core mission from day one.[1]